SCHEMBL10176264

SCHEMBL10176264

CC(C)(C)c1ccc(-n2c(N)nc3ccccc32)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.49
HTT P42858 2/20 0.46
MAPK1 P28482 1/20 0.46
AKT1 P31749 1/20 0.46
AKT2 P31751 1/20 0.46
AKT3 Q9Y243 1/20 0.46
NOS2 P35228 1/20 0.46
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
POLB P06746 2/20 0.43
TP53 P04637 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
RPS6KB1 P23443 2/20 0.42
ROCK1 Q13464 2/20 0.42
SLC22A12 Q96S37 1/20 0.42
CXCR4 P61073 1/20 0.41
TLR8 Q9NR97 2/20 0.41
NOD1 Q9Y239 1/20 0.41
ESR1 P03372 1/20 0.40
ESR2 Q92731 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29508930 0.84 NOD1 (0.57) ADORA2AHTTMAPK1NOS2CYP1A2
SCHEMBL16826857 0.84 NOD1 (0.57) ADORA2AHTTMAPK1NOS2CYP1A2
SCHEMBL25782620 0.83 MAPK1 (0.70) ADORA2AHTTMAPK1AKT1AKT2
SCHEMBL15214855 0.82 L3MBTL1 (0.56) ADORA2AHTTMAPK1NOS2CYP1A2
SCHEMBL7168183 0.82 NOS2 (0.53) ADORA2AHTTMAPK1NOS2CYP1A2
SCHEMBL2309144 0.81 MAPK1 (0.61) HTTMAPK1NOS2CYP1A2CYP2D6
Hydrochloric Acid SCHEMBL7167676 0.80 NOS2 (0.52) ADORA2AHTTMAPK1NOS2CYP1A2
SCHEMBL26017755 0.80 ESR2 (0.60) ADORA2AHTTMAPK1AKT1AKT2
SCHEMBL19374106 0.79 ESR1 (0.67) ADORA2AHTTMAPK1AKT1AKT2
SCHEMBL14947867 0.79 ESR2 (0.55) ADORA2AHTTMAPK1AKT1AKT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9067928-B2 Compounds and methods of use ABBVIE INC. (US) 2015-06-30 US disclosed
US-8518970-B2 Compounds and methods of use ABBVIE INC. (US) 2013-08-27 US disclosed
US-8232273-B2 Heterocyclic compounds and methods of use GENENTECH, INC. (US) 2012-07-31 US disclosed
US-8232273-B2 Heterocyclic compounds and methods of use GENENTECH, INC. (US) 2012-07-31 US disclosed
US-20120184541-A1 COMPOUNDS AND METHODS OF USE ABBVIE INC. 2012-07-19 US disclosed
US-20120184541-A1 COMPOUNDS AND METHODS OF USE ABBVIE INC. 2012-07-19 US disclosed
US-8114893-B2 Compounds and methods of use GENENTECH, INC. (US) 2012-02-14 US disclosed
US-8114893-B2 Compounds and methods of use GENENTECH, INC. (US) 2012-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184541-A1 COMPOUNDS AND METHODS OF USE BCL2A1, BCL2, BAX ADORA2A 1265/4885HTT 3456/4885MAPK1 3552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.